 2020 Q3 Earnings Call Summary

West Pharmaceuticals reported strong financial results in Q3 2020, with organic sales growth of 18% and a contract manufacturing gross profit margin of 17.9%. The company's full-year net sales guidance is between $2.1 billion and $2.11 billion, with an estimated organic sales growth of 14% to 15%. The adjusted diluted earnings per share guidance is between $4.50 and $4.55. West is expanding its HVP manufacturing capacity to meet anticipated 2021 COVID-19 vaccine demand, with capex guidance remaining at $170 million to $180 million. The company received FDA clearance for its 20 millimeter Vial2Bag advanced product. West is focused on delivering value to all stakeholders and supporting the healthcare industry in resolving the global pandemic.